13 October 2017
EMEA/692028/2017

Public statement

Clopidogrel Teva Pharma

Withdrawal of the marketing authorisation in the European Union

On 15 June 2017, the European Commission withdrew the marketing authorisation for Clopidogrel Teva Pharma (clopidogrel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva Pharma B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Clopidogrel Teva Pharma was granted marketing authorisation in the EU on 21 September 2009 for prevention of atherothrombotic events in patients suffering from myocardial infarction. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Clopidogrel Teva Pharma is a generic medicine of Plavix. There are other generic medicinal products of Plavix authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Clopidogrel Teva Pharma will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.